A disruptive technology to tackle brain cancer and glioblastoma
News
Hemerion Makes Its Debut at the American Association of Neurological Surgeons (AANS) Annual Meeting
Hemerion is participating for the first time in the American Association of Neurological Surgeons (AANS) Annual Meeting, held in San Antonio, Texas, from May 1 to 4, 2026.This major event… ...
Hemerion strengthens its management to accelerate clinical development
After receiving several positive feedback from European and US health agencies, Hemerion is preparing to scale up its teams for the implementation of a pivotal clinical trial, the last step… ...
Positive FDA feedback on Hemerion’s clinical strategy for glioblastoma
The Food and Drug Administration (FDA) has issued a positive feedback on Hemerion’s clinical strategy following a Type C Meeting held in November 2025. The U.S. health authority confirmed the… ...
Stay tuned to our clinical advances
They talk about us
